$10,513.84 consulting Payment -- Amgen Inc to Dr. Lisa Garcia
Cardiologist Lisa Garcia Receives $10,513.84 Consulting Fee from Amgen for Rinvoq
This page provides a detailed analysis of a $10,513.84 consulting payment from Amgen Inc to Dr. Lisa Garcia. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $10,513.84 |
| Payment Type | consulting |
| Payment Nature | Consulting Fee |
| Pharmaceutical Company | Amgen Inc |
| Physician | Dr. Lisa Garcia |
| NPI Number | 1457922705 |
| Physician Specialty | Cardiology |
| Location | Winston-Salem, NC |
| Date of Payment | 2024-12-24 |
| Related Drug/Device | Rinvoq |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Amgen Inc made a $10.5K consulting payment to Lisa Garcia, a Cardiology specialist in Winston-Salem, NC. The payment was associated with Rinvoq. The payment of $10,513.84 to Dr. Lisa Garcia from Amgen Inc. is for consulting services related to Rinvoq. This payment occurred on December 24, 2024, indicating a recent engagement. The consulting fee is specifically tied to the drug Rinvoq, suggesting a focus on its development or promotion.
Patient Guidance: What This Payment Means for You
This information details a payment made to a healthcare provider for consulting services. It is important to understand how such payments might influence medical advice. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Consulting fees for cardiologists can vary widely based on expertise and the specific project, but this amount represents a significant engagement.
Regulatory Context: Sunshine Act Requirements
Payments to physicians for consulting services are subject to disclosure under the Sunshine Act, requiring transparency in financial relationships between healthcare providers and industry.
Related Topics
This payment is related to the following healthcare transparency topics:
- consulting-fees
- pharma-payments
- cardiologist
- amgen
- rinvoq
- physician-compensation
Understanding consulting Payments
Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.
Frequently Asked Questions About This Payment
What was this $10.5K payment for?
This was a consulting payment of $10.5K from Amgen Inc to Lisa Garcia, categorized as "Consulting Fee". It was associated with Rinvoq. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Lisa Garcia accept pharmaceutical money?
Yes, Lisa Garcia received this $10.5K payment from Amgen Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Lisa Garcia's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this consulting payment?
A consulting payment of $10.5K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Cardiology?
To compare this payment against Cardiology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Cardiology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Lisa Garcia's relationship with Amgen Inc?
The payment amount is a specific figure, suggesting a defined scope of work for the consulting services. This $10.5K consulting payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Cardiology?
The payment date is close to the end of the year, which could be relevant for financial reporting.
What should patients do after learning about this payment?
This information details a payment made to a healthcare provider for consulting services. It is important to understand how such payments might influence medical advice.
What else should I know about this consulting payment?
The engagement is categorized as a 'Consulting Fee,' implying an advisory role rather than promotional activities.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.